Two types of genetic risk scores (GRS) have been devised to identify patients who will benefit most from cardiovascular-drug treatment: one related to the intermediate phenotype within a causal pathway, and another related to the expected clinical event. These GRS are promising and might have clinical implications for future practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Postmus, I. et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat. Commun. 5, 5068 (2014).
Postmus, I. et al. In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study. Atherosclerosis 235, 58–64 (2014).
Smit, R. A., Trompet, S., de Craen, A. J. & Jukema, J. W. Using genetic variation for establishing causality of cardiovascular risk factors: overcoming confounding and reverse causality. Neth. Heart J. 22, 186–189 (2014).
Willer. C. J. et al. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274–1283 (2013).
Mega, J. L. et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet http://dx.doi.org/10.1016/S0140-6736(14)61730-X.
Pierce, B. L., Ahsan, H. & Vanderweele, T. J. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int. J. Epidemiol. 40, 740–752 (2011).
Burgess, S. & Thompson, S. G. Use of allele scores as instrumental variables for Mendelian randomization. Int. J. Epidemiol. 42, 1134–1144 (2013).
Shepherd, J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623–1630 (2002).
Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837–1847 (1998).
Perk, J. et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 33, 1635–1701 (2012).
Acknowledgements
We thank Roelof Smit and Ton de Craen from the Leiden University Medical Center, Leiden, Netherlands, for their valuable contributions to this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Jukema, J., Trompet, S. Genetic risk scores—new promises for drug evaluation. Nat Rev Cardiol 12, 321–322 (2015). https://doi.org/10.1038/nrcardio.2015.62
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2015.62
